MYH13

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, MYH13 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYH13 data layer compared with 21 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MYH13 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYH13 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC and HNSC are the cancer types where MYH13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LSCCOSMedianIII,IV0.0650.812.0456view →
HNSCDFSTertileIII,IV1.0000.900.0412view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYH13–LSCC (OS)

Kaplan–Meier survival curve for MYH13 mass-spec protein-high vs -low samples in LSCC.

Open the LSCC breakdown →

Exploration